Angelika Starzer, MD, Medical University of Vienna, Vienna, Austria, provides an overview of therapies for breast cancer with brain metastases, including data from the Phase III HER2CLIMB-02 (NCT03975647) trial suggesting a positive benefit of tucatinib in HER2-positve breast cancer, which included patients with brain metastases. Data is indicating trastuzumab deruxtecan may also provide a benefit for breast cancer with brain metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.